Post-symptomatic antidotes to botulinum neurotoxin(PSABS)
Ended Definitive Contract Awarded Last action
- Contract number
- 140D6318C0114
- Awardee
-
Cytodel, Inc. UEI C1AUXSRGH7W5
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $1,429,034
Award facts
- Opportunity
-
- SBIR132 Solicitation number
- Contract value 100% obligated
- $1,429,034.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Advanced Research Projects Agency Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10016, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Other statutory authority
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,429,034 |
About this award
This is a Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Cytodel Inc., a self-certified small disadvantaged business, for the development of post-symptomatic antidotes to botulinum neurotoxin (PSABS). The $1,429,034 contract is set aside for small businesses and is part of DARPA's SBIR (Small Business Innovation Research) Phase II program. Cytodel specializes in developing recombinant botulinum toxin derivatives and has received prior grant funding from the National Institutes of Health for related work. The contract aims to establish an animal model for botulinum neurotoxin serotype A1 overdose and develop an antibody-botulinum toxin fusion protein as a treatment, as well as test a recombinant botulinum neurotoxin A1 derivative for treating dystonia. Cytodel has also received a sub-award to conduct murine testing of botulinum toxin antibodies and advance lead candidates.
Quick answers
Who was awarded contract 140D6318C0114?
140D6318C0114 was awarded to Cytodel, Inc. by Interior Business Center (Office of Policy Management and Budget) on August 28, 2018.
How much is contract 140D6318C0114 worth?
The government has obligated $1,429,034 on 140D6318C0114.
Which agency awarded contract 140D6318C0114?
Interior Business Center (Office of Policy Management and Budget) awarded 140D6318C0114, with funding from Defense Advanced Research Projects Agency (Department of Defense).
Was contract 140D6318C0114 competed?
The extent of competition for 140D6318C0114 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award